- Home
- Publications
- Publication Search
- Publication Details
Title
Small molecules targeting phosphoinositide 3-kinases
Authors
Keywords
-
Journal
MedChemComm
Volume 3, Issue 11, Pages 1337
Publisher
Royal Society of Chemistry (RSC)
Online
2012-05-11
DOI
10.1039/c2md20044a
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A first-in-human phase I study of intravenous PI3K inhibitor BAY 80-6946 in patients with advanced solid tumors: Results of dose-escalation phase.
- (2017) A. Patnaik et al. JOURNAL OF CLINICAL ONCOLOGY
- Regulation and Importance of the PI3K/Akt/mTOR Signaling Pathway in Hematologic Malignancies
- (2012) Kiyotaka Kawauchi et al. Anti-Cancer Agents in Medicinal Chemistry
- Discovery of novel 2-piperidinol-3-(arylsulfonyl)quinoxalines as phosphoinositide 3-kinase α (PI3Kα) inhibitors
- (2012) Peng Wu et al. BIOORGANIC & MEDICINAL CHEMISTRY
- NVP-BEZ235 and NVP-BGT226, dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitors, enhance tumor and endothelial cell radiosensitivity
- (2012) Emmanouil Fokas et al. Radiation Oncology
- Discovery of novel morpholino–quinoxalines as PI3Kα inhibitors by pharmacophore-based screening
- (2012) Peng Wu et al. MedChemComm
- Simultaneous targeting of PI3K and mTOR with NVP-BGT226 is highly effective in multiple myeloma
- (2011) Philipp Baumann et al. ANTI-CANCER DRUGS
- A drug targeting only p110α can block phosphoinositide 3-kinase signalling and tumour growth in certain cell types
- (2011) Stephen Jamieson et al. BIOCHEMICAL JOURNAL
- Discovery and biological activity of a novel class I PI3K inhibitor, CH5132799
- (2011) Jun Ohwada et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Structure-based virtual screening approach to the discovery of phosphoinositide 3-kinase alpha inhibitors
- (2011) Hwangseo Park et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Identification of 2-oxatriazines as highly potent pan-PI3K/mTOR dual inhibitors
- (2011) Christoph M. Dehnhardt et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Structure-based design of thienobenzoxepin inhibitors of PI3-kinase
- (2011) Steven T. Staben et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Antitumor Activity of NVP-BKM120--A Selective Pan Class I PI3 Kinase Inhibitor Showed Differential Forms of Cell Death Based on p53 Status of Glioma Cells
- (2011) D. Koul et al. CLINICAL CANCER RESEARCH
- Novel Phosphoinositide 3-Kinase/mTOR Dual Inhibitor, NVP-BGT226, Displays Potent Growth-Inhibitory Activity against Human Head and Neck Cancer Cells In Vitro and In Vivo
- (2011) K.-Y. Chang et al. CLINICAL CANCER RESEARCH
- Antitumor Efficacy of PKI-587, a Highly Potent Dual PI3K/mTOR Kinase Inhibitor
- (2011) R. Mallon et al. CLINICAL CANCER RESEARCH
- Present and Future of PI3K Pathway Inhibition in Cancer: Perspectives and Limitations
- (2011) E. Ciraolo et al. CURRENT MEDICINAL CHEMISTRY
- Progress in the Preclinical Discovery and Clinical Development of Class I and Dual Class I/IV Phosphoinositide 3-Kinase (PI3K) Inhibitors
- (2011) S. J. Shuttleworth et al. CURRENT MEDICINAL CHEMISTRY
- Synthesis and biological evaluation of novel 2-arylamino-3-(arylsulfonyl)quinoxalines as PI3Kα inhibitors
- (2011) Peng Wu et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- CAL-101: a phosphatidylinositol-3-kinase p110-delta inhibitor for the treatment of lymphoid malignancies
- (2011) Jorge J Castillo et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors
- (2011) Johanna C. Bendell et al. JOURNAL OF CLINICAL ONCOLOGY
- Discovery and Optimization of a Series of Benzothiazole Phosphoinositide 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Dual Inhibitors
- (2011) Noel D. D’Angelo et al. JOURNAL OF MEDICINAL CHEMISTRY
- Structure–Activity Relationships of Phosphoinositide 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Dual Inhibitors: Investigations of Various 6,5-Heterocycles to Improve Metabolic Stability
- (2011) Markian M. Stec et al. JOURNAL OF MEDICINAL CHEMISTRY
- Phospshoinositide 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Dual Inhibitors: Discovery and Structure–Activity Relationships of a Series of Quinoline and Quinoxaline Derivatives
- (2011) Nobuko Nishimura et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of a Potent, Selective, and Orally Available Class I Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Kinase Inhibitor (GDC-0980) for the Treatment of Cancer
- (2011) Daniel P. Sutherlin et al. JOURNAL OF MEDICINAL CHEMISTRY
- Design and Synthesis of Imidazopyridine Analogues as Inhibitors of Phosphoinositide 3-Kinase Signaling and Angiogenesis
- (2011) Okseon Kim et al. JOURNAL OF MEDICINAL CHEMISTRY
- Novel phosphatidylinositol 3-kinase inhibitor NVP-BKM120 induces apoptosis in myeloma cells and shows synergistic anti-myeloma activity with dexamethasone
- (2011) Yuhuan Zheng et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor
- (2011) S.-M. Maira et al. MOLECULAR CANCER THERAPEUTICS
- Structure of Lipid Kinase p110β/p85β Elucidates an Unusual SH2-Domain-Mediated Inhibitory Mechanism
- (2011) Xuxiao Zhang et al. MOLECULAR CELL
- Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors
- (2011) A. Chakrabarty et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer
- (2011) Matthew T. Burger et al. ACS Medicinal Chemistry Letters
- Identification of GNE-477, a potent and efficacious dual PI3K/mTOR inhibitor
- (2010) Timothy P. Heffron et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- 4-Methylpteridinones as orally active and selective PI3K/mTOR dual inhibitors
- (2010) Kevin K.-C. Liu et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Quinazolines with intra-molecular hydrogen bonding scaffold (iMHBS) as PI3K/mTOR dual inhibitors
- (2010) Kevin K.C. Liu et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Discovery of novel class 1 phosphatidylinositide 3-kinases (PI3K) fragment inhibitors through structure-based virtual screening
- (2010) Fabrizio Giordanetto et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- CAL-101, a p110 selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability
- (2010) B. J. Lannutti et al. BLOOD
- PI3K/Akt/mTOR Pathway Inhibitors in Cancer: A Perspective on Clinical Progress
- (2010) P. Wu et al. CURRENT MEDICINAL CHEMISTRY
- Design, Synthesis, and Structure−Activity Relationships of 3-Ethynyl-1H-indazoles as Inhibitors of the Phosphatidylinositol 3-Kinase Signaling Pathway
- (2010) Elisa Barile et al. JOURNAL OF MEDICINAL CHEMISTRY
- Bis(morpholino-1,3,5-triazine) Derivatives: Potent Adenosine 5′-Triphosphate Competitive Phosphatidylinositol-3-kinase/Mammalian Target of Rapamycin Inhibitors: Discovery of Compound26(PKI-587), a Highly Efficacious Dual Inhibitor
- (2010) Aranapakam M. Venkatesan et al. JOURNAL OF MEDICINAL CHEMISTRY
- The p110δ structure: mechanisms for selectivity and potency of new PI(3)K inhibitors
- (2010) Alex Berndt et al. Nature Chemical Biology
- mTOR signaling and drug development in cancer
- (2010) Janet Dancey Nature Reviews Clinical Oncology
- Discovery of the highly potent PI3K/mTOR dual inhibitor PF-04691502 through structure based drug design
- (2010) Hengmiao Cheng et al. MedChemComm
- Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin
- (2010) Steven D. Knight et al. ACS Medicinal Chemistry Letters
- In vitro evaluation of pan-PI3-kinase inhibitor SF1126 in trastuzumab-sensitive and trastuzumab-resistant HER2-over-expressing breast cancer cells
- (2009) Tuba Ozbay et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- PI3K Inhibitors for Cancer Therapy: What has been Achieved So Far?
- (2009) Peng Wu et al. CURRENT MEDICINAL CHEMISTRY
- Should individual PI3 kinase isoforms be targeted in cancer?
- (2009) Shidong Jia et al. CURRENT OPINION IN CELL BIOLOGY
- PI 3-kinase and cancer: changing accents
- (2009) Peter K Vogt et al. CURRENT OPINION IN GENETICS & DEVELOPMENT
- ATP-Competitive Inhibitors of the Mammalian Target of Rapamycin: Design and Synthesis of Highly Potent and Selective Pyrazolopyrimidines
- (2009) Arie Zask et al. JOURNAL OF MEDICINAL CHEMISTRY
- Lead Optimization of N-3-Substituted 7-Morpholinotriazolopyrimidines as Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitors: Discovery of PKI-402
- (2009) Christoph M. Dehnhardt et al. JOURNAL OF MEDICINAL CHEMISTRY
- Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941
- (2009) F. I. Raynaud et al. MOLECULAR CANCER THERAPEUTICS
- A frequent kinase domain mutation that changes the interaction between PI3K and the membrane
- (2009) D. Mandelker et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Imidazo[4,5-c]quinolines as inhibitors of the PI3K/PKB-pathway
- (2008) Frédéric Stauffer et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Design and synthesis of novel furoquinoline based inhibitors of multiple targets in the PI3K/Akt-mTOR pathway
- (2008) Manoj V. Lohar et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Achieving multi-isoform PI3K inhibition in a series of substituted 3,4-dihydro-2H-benzo[1,4]oxazines
- (2008) Benjamin Perry et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- 4-(1,3-Thiazol-2-yl)morpholine derivatives as inhibitors of phosphoinositide 3-kinase
- (2008) Rikki Alexander et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- A Vascular Targeted Pan Phosphoinositide 3-Kinase Inhibitor Prodrug, SF1126, with Antitumor and Antiangiogenic Activity
- (2008) J. R. Garlich et al. CANCER RESEARCH
- The Identification of 2-(1H-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer†
- (2008) Adrian J. Folkes et al. JOURNAL OF MEDICINAL CHEMISTRY
- Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer
- (2008) Johan Bussink et al. LANCET ONCOLOGY
- Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity
- (2008) S.-M. Maira et al. MOLECULAR CANCER THERAPEUTICS
- Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases
- (2008) Beth Apsel et al. Nature Chemical Biology
- Drug discovery approaches targeting the PI3K/Akt pathway in cancer
- (2008) C Garcia-Echeverria et al. ONCOGENE
- Taming the PI3K team to hold inflammation and cancer at bay
- (2008) Emilio Hirsch et al. PHARMACOLOGY & THERAPEUTICS
- PTEN-deficient cancers depend on PIK3CB
- (2008) S. Wee et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Targeting phosphoinositide 3-kinase—Moving towards therapy
- (2007) Romina Marone et al. BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now